On April 22, American pharmaceutical company Pfizer and German biotechnology company BioNTech announced that the BNT162 new coronal pneumonia vaccine jointly developed by the two companies was approved by the Paul Ehrlich Institute of the German Federal Institute for Vaccine and Biomedicine and will be launched in the country Clinical Trials. This is also Germany’s first clinical trial of a new candidate vaccine against coronary pneumonia.
The two companies mentioned in the announcement that during the clinical development stage, BioNTech will cooperate through its GMP (production quality management practice) certified mRNA production facility in Europe Partners provide clinical supply of vaccines. In addition, as part of a global plan, Pfizer and BioNTech will also conduct new crown vaccine trials in the United States, which is expected to soon receive regulatory approval.
Reuters quoted the German vaccine regulator on the same day as saying that Germany has approved a clinical trial of a new coronary pneumonia vaccine. The candidate vaccine is produced by the German biotechnology company BioNTech. In the first phase of clinical trials, 200 volunteers between the ages of 18 and 55 will receive several different vaccines. In addition, a second phase clinical trial is also planned for suspected patients with new coronary pneumonia and severe patients.
Affected by the news, as of press time, BioNTech ’s pre-market rise in US stocks expanded to 47.87% to $ 62.45 per share.
BioNTech was founded in 2008 and is headquartered in Mainz, Germany. It mainly develops personalized immunotherapy for cancer patients, infectious diseases and chronically infected patients. It is mRNA therapy. One of the main pathfinders. The company was once the largest biotech unicorn in Europe and was listed on the Dasdaq in October 2019.
BioNTech disclosed the latest development progress of its new coronary pneumonia mRNA vaccine in March. For the candidate vaccine named BNT162, the company plans to conduct global clinical trials from the end of April after obtaining regulatory approvals, including Europe (from Germany), the United States and China.
On March 16, BioNTech announced that it has reached a cooperation with Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. The cooperation content includes clinical trials and subsequent commercialization of BNT162 in China. On March 17, BioNTech and Pfizer issued a joint statement that they will jointly develop experimental vaccines for the new coronavirus. The two companies have signed an agreement of intent to provide vaccines to all countries except China.